Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant

References

• Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 2001;98(6):1687–1694.
   PubMed Web of Science ®Google Scholar
• Worel N, Kalhs P, Keil F, et al. ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion. 2003;43(8):1153–1161.
   PubMed Web of Science ®Google Scholar
• Bruno B, Gooley T, Sullivan KM, et al. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7(3):154–162.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010;116(22):4693–4699.
   PubMed Web of Science ®Google Scholar
• Rocha V, Gluckman E, Eurocord-Netcord registry and European Blood and Marrow Transplant Group. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol. 2009;147(2):262–274.
   PubMed Web of Science ®Google Scholar
• Mielcarek M, Leisenring W, Torok-Storb B, et al. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood. 2000;96(3):1150–1156.
   PubMed Web of Science ®Google Scholar
• Verdonck LF, de Gast GC, van Heugten HG, et al. Cytomegalovirus infection causes delayed platelet recovery after bone marrow transplantation. Blood. 1991;78(3):844–848.
   PubMed Web of Science ®Google Scholar
• Hirokawa M, Fukuda T, Ohashi K, et al. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant. 2013;19(7):1026–1032.
   PubMed Web of Science ®Google Scholar
• Worel N, Greinix HT, Schneider B, et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion. 2000;40(5):543–550.
   PubMed Web of Science ®Google Scholar
• Gmur JP, Burger J, Schaffner A, et al. Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood. 1990;75(1):290–295.
   PubMed Web of Science ®Google Scholar
• van Besien K, Kunavakkam R, Rondon G, et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009;15(5):610–617.
   PubMed Web of Science ®Google Scholar
• Shaw BE, Gooley TA, Malkki M, Madrigal JA, Begovich AB, et al. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood. 2007;110(13):4560–4566.
   PubMed Web of Science ®Google Scholar
• Crocchiolo R, Zino E, Vago L, et al. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood. 2009;114(7):1437–1444.
   PubMed Web of Science ®Google Scholar
• Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood. 2011;117(8):2332–2339.
   PubMed Web of Science ®Google Scholar
• Eapen M, Klein JP, Ruggeri A, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014;123(1):133–140.
   PubMed Web of Science ®Google Scholar
• Van Besien K, Liu H, Jain N, et al. Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant. 2013;19(5):682–691. e-pub ahead of print 2012/11/13;
   PubMed Web of Science ®Google Scholar
• Yoshihara S, Taniguchi K, Ogawa H, et al. The role of HLA antibodies in allogeneic SCT: is the ‘type-and-screen’ strategy necessary not only for blood type but also for HLA? Bone Marrow Transplant. 2012;47(12):1499–1506.
   PubMed Web of Science ®Google Scholar
• Gergis U, Mayer S, Gordon B, et al. A strategy to reduce donor-specific HLA Abs before allogeneic transplantation. Bone Marrow Transplant. 2014;49(5):722–724.
   PubMed Web of Science ®Google Scholar
• Kline J, Pollyea DA, Stock W, et al. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant. 2006;37(3):307–310.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
   PubMed Web of Science ®Google Scholar
• Nakamae H, Storer B, Sandmaier BM, et al. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica. 2011;96(12):1838–1845.
   PubMed Web of Science ®Google Scholar
• Kim DH, Sohn SK, Jeon SB, et al. Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD. Bone Marrow Transplant. 2006;37(1):101–108.
   PubMed Web of Science ®Google Scholar
• Anasetti C, Rybka W, Sullivan KM, et al. Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood. 1989;73(4):1054–1058.
   PubMed Web of Science ®Google Scholar
• Nishimoto T, Kuwana M. CD4 + CD25 + Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia. Semin Hematol. 2013;50(Suppl 1):S43–S49.
   PubMedGoogle Scholar
• Seebach JD, Stussi G, Passweg JR, et al. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant. 2005;11(12):1006–1013.
   PubMed Web of Science ®Google Scholar
• Goldman J, Liesveld J, Nichols D, et al. ABO incompatibility between donor and recipient and clinical outcomes in allogeneic stem cell transplantation. Leuk Res. 2003;27(6):489–491.
   PubMed Web of Science ®Google Scholar
• Canals C, Muñiz-Díaz E, Martínez C, et al. Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning. Transfusion. 2004;44(11):1603–1611.
   PubMed Web of Science ®Google Scholar
• Klumpp TR, Herman JH, Ulicny J, et al. Lack of effect of donor-recipient ABO mismatching on outcome following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;38(9):615–620.
   PubMed Web of Science ®Google Scholar
• Sniecinski IJ, Oien L, Petz LD, et al. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation. 1988;45(3):530–534.
   PubMed Web of Science ®Google Scholar
• Benjamin RJ, Connors JM, McGurk S, et al. Prolonged erythroid aplasia after major ABO-mismatched transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant. 1998;4(3):151–156.
   PubMedGoogle Scholar
• Bär BM, Van Dijk BA, Schattenberg A, et al. Erythrocyte repopulation after major ABO incompatible transplantation with lymphocyte-depleted bone marrow. Bone Marrow Transplant. 1995;16(6):793–799.
   PubMed Web of Science ®Google Scholar
• Klumpp TR. Immunohematologic complications of bone marrow transplantation. Bone Marrow Transplant. 1991;8(3):159–170.
   PubMed Web of Science ®Google Scholar
• Wang Z, Sorror ML, Leisenring W, et al. The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation. Br J Haematol. 2010;149(1):101–110.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061–1070.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282–288.
   PubMed Web of Science ®Google Scholar
• Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011;118(24):6438–6445.
   PubMed Web of Science ®Google Scholar
• Magro E, Regidor C, Cabrera R, et al. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor. Haematologica. 2006;91:640–648.
   PubMed Web of Science ®Google Scholar